Tinlarebant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tinlarebant Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Tinlarebant can convert its Small molecule drug profile and RBP4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tinlarebant (query alias: Tinlarebant) |
|---|---|
| Modality / target | Small molecule drug; RBP4; RBP4 inhibitors |
| Highest global status | NDA/BLA |
| Originator | The Trustees of Columbia University in The City of New York |
| Active developers | Bei Liang Bio-Pharmaceutical (Shanghai) Co., Ltd., Belite Bio, Inc., The Trustees of Columbia University in The City of New York |
The MCP disease footprint includes Stargardt Disease, Geographic Atrophy, Age Related Macular Degeneration. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05949593 | Phase 3 | Active, not recruiting | 429 | To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size |
| NCT06388083 | Phase 2/3 | Active, not recruiting | 60 | To measure the annualized rate of change from baseline lesion size in aggregate area of atrophy |
| NCT05667688 | Phase 1 | Completed | 15 | To measure the pharmacokinetics (PK) of tinlarebant in plasma following a single oral dose in healthy volunteers aged 50-85. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
Phase 3; n=104; evaluation: Positive. Reported fields: Growth rate of atrophic retinal lesions(DDAF, study eye): Difference (%) = -35.7, P-Value = 0.0033 Met; Growth rate of atrophic retinal lesions(DDAF, study eye): Difference (%) = -35.7, P-Value = 0.0033 Met
Investigation of an Oral Retinol Binding Protein 4 Antagonist in the Treatment of Childhood-onset Stargardt Disease
Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: Delayed dark adaptation = Delayed dark adaptation (9 of 13 subjects [69.2%]) were most frequently reported
Safety, Tolerability, and Efficacy of Tinlarebant from the 24-Month Phase 2 study in Adolescent Patients Affected by Stargardt Disease
临床2期; n=12; evaluation: 积极. Reported fields: New Gd+ lesions = 42 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tinlarebant addresses Stargardt Disease, Geographic Atrophy, Age Related Macular Degeneration. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2017-01-06 | Lin Bioscience Licenses First-in-Class Therapeutic Program to treat Dry Aged-Related Macular Degeneration from Columbia University in Collaboration with NIH | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Formulations of RBP4 inhibitors and methods of use”. The milestone feed surfaced a patent-application signal described as “Tablet formulations of RBP4 inhibitors and methods of use”. The milestone feed surfaced a patent-application signal described as “RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
